MSTSUKI TAKASHI 松木崇

… Alternative Names

Matsuki Takashi 松木崇

Less

Researcher Number	00525511
Other IDs
Affiliation (Current)	2025: 地方独立行政法人神奈川県立病院機構神奈川県立がんセンター(臨床研究所), 頭頸部外科, 部長
Affiliation (based on the past Project Information) *help	2024: 地方独立行政法人神奈川県立病院機構神奈川県立がんセンター(臨床研究所), 頭頸部外科, 医長 2021 – 2023: 北里大学, 医学部, 講師 2020: 北里大学, 医学部, 助教
Review Section/Research Field	Principal Investigator Basic Section 50010:Tumor biology-related
Keywords	Principal Investigator 唾液腺導管癌 / HMGA2遺伝子再構成 / PLAG1遺伝子再構成 / 多形腺腫由来癌 / 治療効果予測因子 / ニボルマブ / PDL-1 / ペムブロリズマブ / PD-L1 / ペムブロリズマブ … More / 免疫チェックポイント阻害薬 / 高頻度マイクロサテライト不安定性 / ミスマッチ修復機構 / 腫瘍浸潤リンパ球 / 癌免疫微小環境 Less

Elucidation of the molecular carcinogenesis mechanism of salivary duct carcinoma and its therapeutic strategy basis.Principal Investigator
- Principal Investigator
  
  松木崇
- Project Period (FY)
  2024 – 2026
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 50010:Tumor biology-related
- Research Institution
  Kanagawa Cancer Center Research Institute
Analysis of Tumor-Infiltrating Lymphocytes in Salivary Duct Carcinoma: Significance as Predictive Biomarkers for Therapeutic Response and PrognosisPrincipal Investigator
- Principal Investigator
  
  Matsuki Takashi
- Project Period (FY)
  2020 – 2024
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 50010:Tumor biology-related
- Research Institution
  Kanagawa Cancer Center Research Institute
  Kitasato University

All 2025 2024 2023 2022 2020

All Journal Article Presentation

[Journal Article] PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab2024
- Author(s)
  Matsuki Takashi、Kawakita Daisuke、Takahashi Hideaki、Okada Takuro、Sakai Akihiro、Ueki Yushi、Tsuge Hiroshi、Hanyu Kenji、Momiyama Kaho、Shodo Ryusuke、Yamauchi Mayu、Asako Yukiko、Hirai Hideaki、Nagao Toshitaka、Tada Yuichiro
- Journal Title
  
  Scientific Reports
  
  Volume: 14 Issue: 1 Pages: 19794-19794
- DOI
  10.1038/s41598-024-70779-8
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-20K07597, KAKENHI-PROJECT-21K16835, KAKENHI-PROJECT-22K06969, KAKENHI-PROJECT-23K06432, KAKENHI-PROJECT-22K16935
[Journal Article] Prognostic value and clinicopathological roles of the tumor immune microenvironment in salivary duct carcinoma2023
- Author(s)
  Hirai Hideaki、Nakaguro Masato、Tada Yuichiro、Saigusa Natsuki、Kawakita Daisuke、Honma Yoshitaka、Kano Satoshi、Tsukahara Kiyoaki、Ozawa Hiroyuki、Okami Kenji、Yamazaki Keisuke、Fushimi Chihiro、Kondo Takahito、Imanishi Yorihisa、Sakai Akihiro、Togashi Takafumi、Hanazawa Toyoyuki、Matsuki Takashi、Nagao Toshitaka
- Journal Title
  
  Virchows Archiv
  
  Volume: 483 Issue: 3 Pages: 367-379
- DOI
  10.1007/s00428-023-03598-3
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K07597, KAKENHI-PROJECT-22K06939, KAKENHI-PROJECT-22K10210, KAKENHI-PROJECT-23K06432, KAKENHI-PROJECT-23K08918, KAKENHI-PROJECT-20K09763, KAKENHI-PROJECT-21K09616
[Journal Article] Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma2022
- Author(s)
  OKADA TAKURO、MATSUKI TAKASHI、FUSHIMI CHIHIRO、OKAMOTO ISAKU、SATO HIROKI、KONDO TAKAHITO、TOKASHIKI KUNIHIKO、ITO TATSUYA、MASUBUCHI TATSUO、TADA YUICHIRO、MIURA KOUKI、HANYU KENJI、OMURA GO、TAKAHASHI HIDEKI、YAMASHITA TAKU、ORIDATE NOBUHIKO、TSUKAHARA KIYOAKI
- Journal Title
  
  Anticancer Research
  
  Volume: 42 Issue: 10 Pages: 4907-4912
- DOI
  10.21873/anticanres.15996
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20K07597, KAKENHI-PROJECT-21K09612
[Journal Article] Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma2022
- Author(s)
  Kawakita Daisuke、Nagao Toshitaka、Takahashi Hideaki、Kano Satoshi、Honma Yoshitaka、Hirai Hideaki、Saigusa Natsuki、Akazawa Kohei、Tani Kaori、Ojiri Hiroya、Tsukahara Kiyoaki、Ozawa Hiroyuki、Okami Kenji、Kondo Takahito、Togashi Takafumi、Fushimi Chihiro、Shimura Tomotaka、Matsuki Takashi、Tada Yuichiro
- Journal Title
  
  Therapeutic Advances in Medical Oncology
  
  Volume: 14 Pages: 175883592211195-175883592211195
- DOI
  10.1177/17588359221119538
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-20K07597, KAKENHI-PROJECT-20K09763, KAKENHI-PROJECT-21K09616, KAKENHI-PROJECT-22K06939, KAKENHI-PROJECT-21K16835, KAKENHI-PROJECT-21K16861, KAKENHI-PROJECT-22K16896, KAKENHI-PROJECT-21H02795, KAKENHI-PROJECT-17K08753, KAKENHI-PROJECT-18K09340, KAKENHI-PROJECT-20K07417, KAKENHI-PROJECT-20K10508, KAKENHI-PROJECT-22K06969
[Journal Article] Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma2022
- Author(s)
  OKADA TAKURO、FUSHIMI CHIHIRO、MATSUKI TAKASHI、TSUKAHARA KIYOAKI
- Journal Title
  
  Anticancer Research
  
  Volume: 42 Issue: 3 Pages: 1607-1613
- DOI
  10.21873/anticanres.15635
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20K07597
[Journal Article] The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy2022
- Author(s)
  Saigusa N, Hirai H, Kohsaka S, et al.
- Journal Title
  
  Front Oncol
  
  Volume: 11 Pages: 779882-779882
- DOI
  10.3389/fonc.2021.779882
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-21H02795, KAKENHI-PROJECT-18K09340, KAKENHI-PROJECT-20K07597, KAKENHI-PROJECT-20K09763, KAKENHI-PROJECT-20K10508, KAKENHI-PROJECT-21K09616, KAKENHI-PROJECT-21K16835, KAKENHI-PROJECT-21K16861, KAKENHI-PROJECT-21K09556, KAKENHI-PROJECT-22K10210, KAKENHI-PROJECT-17K08753, KAKENHI-PROJECT-19K16568, KAKENHI-PROJECT-22K06969
[Journal Article] Investigation of the Efficacy and Safety of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma2020
- Author(s)
  SATO HIROKI、FUSHIMI CHIHIRO、OKADA TAKURO、MATSUKI TAKASHI、KONDO TAKAHITO、OMURA GO、MIURA KOUKI、YAMASHITA TAKU、OKAMOTO ISAKU、TSUKAHARA KIYOAKI
- Journal Title
  
  In Vivo
  
  Volume: 34 Issue: 5 Pages: 2967-2972
- DOI
  10.21873/invivo.12127
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20K07597
[Journal Article] Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients.2020
- Author(s)
  Matsuki T, Okamoto I, Fushimi C, Sawabe M, Kawakita D, Sato H, Tsukahara K, Kondo T, Okada T, Tada Y, Miura K, Omura G, Yamashita T
- Journal Title
  
  Cancer Med.
  
  Volume: 9 Issue: 14 Pages: 5015-5024
- DOI
  10.1002/cam4.3124
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-18K09339, KAKENHI-PROJECT-20K07597, KAKENHI-PROJECT-20K10508
[Journal Article] Cite Share Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma.2020
- Author(s)
  Fushimi C, Okamoto I, Matsuki T, Masubuchi T, Okada T, Sato H, Tsukahara K, Kondo T, Yamashita T, Hanyu K, Omura GO, Takahashi H, Tada Y, Miura K.
- Journal Title
  
  Anticancer Res
  
  Volume: 40 Issue: 9 Pages: 5277-5283
- DOI
  10.21873/anticanres.14532
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-18K09339, KAKENHI-PROJECT-20K07597
[Journal Article] Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma2020
- Author(s)
  Niwa Kazutomo、Kawakita Daisuke、Nagao Toshitaka、Takahashi Hideaki、Saotome Takashi、Okazaki Masashi、Yamazaki Keisuke、Okamoto Isaku、Hirai Hideaki、Saigusa Natsuki、Fushimi Chihiro、Okazaki Shin-ichi、Matsui Hirooki、Iwaki Sho、Matsuki Takashi、Tsukahara Kiyoaki、Oridate Nobuhiko、Tada Yuichiro
- Journal Title
  
  Scientific Reports
  
  Volume: 10 Issue: 1 Pages: 16988-16988
- DOI
  10.1038/s41598-020-73965-6
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K07597, KAKENHI-PROJECT-20K10508, KAKENHI-PROJECT-18K09382, KAKENHI-PROJECT-18K09386, KAKENHI-PROJECT-20K07417, KAKENHI-PROJECT-19K16568
[Journal Article] Age‐based efficacy and safety of nivolumab for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter retrospective study2020
- Author(s)
  Kondo Takahito、Okamoto Isaku、Sato Hiroki、Koyama Nobuyuki、Fushimi Chihiro、Okada Takuro、Masubuchi Tatsuo、Miura Kouki、Matsuki Takashi、Yamashita Taku、Omura Go、Takahashi Hideaki、Tsukahara Kiyoaki
- Journal Title
  
  Asia-Pacific Journal of Clinical Oncology
  
  Volume: 16 Issue: 6 Pages: 340-347
- DOI
  10.1111/ajco.13374
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20K07597
[Journal Article] Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients.2020
- Author(s)
  Matsuki T, Okamoto I, Fushimi C, Takahashi H, Okada T, Kondo T, Sato H, Ito T, Tokashiki K, Tsukahara K, Hanyu K, Masubuchi T, Tada Y, Miura K, Omura G, Sawabe M, Kawakita D, Yamashita T
- Journal Title
  
  Cancers
  
  Volume: 12 Issue: 11 Pages: 3427-3427
- DOI
  10.3390/cancers12113427
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-18K09339, KAKENHI-PROJECT-20K07597, KAKENHI-PROJECT-20K10508, KAKENHI-PROJECT-20K18331
[Presentation] 再発転移唾液腺癌に対するPembrolizumab療法の有効性とPD-L1発現のバイオマーカーとしての役割2025
- Author(s)
  松木　崇
- Organizer
  第49回日本頭頸部癌学会総会・学術講演会
- Data Source
  KAKENHI-PROJECT-20K07597
[Presentation] ニボルマブを投与した再発・転移頭頸部扁平上皮癌症例の年齢別の有効性と安全性の検討－多施設共同研究－2020
- Author(s)
  近藤貴仁、岡本伊作、佐藤宏樹、岡田拓朗、伏見千宙、増淵達夫、三浦弘規、松木崇、山下拓、小村豪、高橋秀聡、塚原清彰
- Organizer
  第44回日本頭頸部癌学会
- Data Source
  KAKENHI-PROJECT-20K07597
[Presentation] 再発転移唾液腺癌に対するカルボプラチン、ドセタキセル併用療法の有効性と安全性の検討2020
- Author(s)
  岡田拓朗、五月女隆、長尾俊孝、増淵達夫、伏見千宙、松木崇、高橋秀聡、三浦弘規、塚原清彰、多田雄一郎
- Organizer
  第44回日本頭頸部癌学会
- Data Source
  KAKENHI-PROJECT-20K07597

1. 多田雄一郎 (70292430)

# of Collaborated Projects: 2 results

# of Collaborated Products: 6 results
2. 長尾俊孝 (90276709)

# of Collaborated Projects: 2 results

# of Collaborated Products: 5 results
3. 平井秀明 (00770744)

# of Collaborated Projects: 1 results

# of Collaborated Products: 4 results
4. 川北大介 (70584506)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
5. 小村豪

# of Collaborated Projects: 0 results

# of Collaborated Products: 3 results
6. 高阪真路

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

MSTSUKI TAKASHI 松木 崇

Matsuki Takashi 松木 崇

Research Projects

Research Products

Co-Researchers

Elucidation of the molecular carcinogenesis mechanism of salivary duct carcinoma and its therapeutic strategy basis.Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Analysis of Tumor-Infiltrating Lymphocytes in Salivary Duct Carcinoma: Significance as Predictive Biomarkers for Therapeutic Response and PrognosisPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

[Journal Article] PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab2024

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Prognostic value and clinicopathological roles of the tumor immune microenvironment in salivary duct carcinoma2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Investigation of the Efficacy and Safety of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma2020

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients.2020

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Cite Share Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma.2020

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma2020

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Age‐based efficacy and safety of nivolumab for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter retrospective study2020

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients.2020

Author(s)

Journal Title

DOI

Data Source

[Presentation] 再発転移唾液腺癌に対するPembrolizumab療法の有効性とPD-L1発現のバイオマーカー としての役割2025

Author(s)

Organizer

MSTSUKI TAKASHI 松木崇

Matsuki Takashi 松木崇

[Presentation] 再発転移唾液腺癌に対するPembrolizumab療法の有効性とPD-L1発現のバイオマーカーとしての役割2025